Literature DB >> 15816518

A comparison of response to cisplatin, radiation and combined treatment for cells deficient in recombination repair pathways.

G P Raaphorst1, Maude Leblanc, L F Li.   

Abstract

The responses of cells with mutated DNA repair pathways were compared for cisplatin, radiation and combination treatments. The knockout of the nonhomologous endjoining (NHEJ) pathway resulted in increased radiation sensitivity, but no change in cisplatin response in the mouse cells and increased radiosensitivity but decreased cisplatin sensitivity in chicken cells. The mutation of the homologous recombination repair (HR) pathway through XRCC3 in CHO cells resulted in increased radiation and cisplatin sensitivity and to a lesser extent for the Rad54 knockout in the DT40 chicken cells. The combination treatments of cisplatin and radiation showed that inhibition of the HR repair pathway resulted in super additive effects while the inhibition of the NHEJ pathway in DT40 had no effect. In mouse cells the knockout of the NHEJ pathway resulted in reduced super additivity compared to the parental cell lines. These data show that radiation, cisplatin and combination treatment damage is affected differently by the various DNA repair pathways, which could have a range of effects on combination treatments in tumour cells expressing different levels of DNA repair in the various repair pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816518

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  HDAC10 as a potential therapeutic target in ovarian cancer.

Authors:  Muhtadi M Islam; Tapahsama Banerjee; Colin Z Packard; Shweta Kotian; Karuppaiyah Selvendiran; David E Cohn; Jeffrey D Parvin
Journal:  Gynecol Oncol       Date:  2017-01-07       Impact factor: 5.482

2.  Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathways.

Authors:  Catherine R Sears; John J Turchi
Journal:  J Biol Chem       Date:  2012-05-23       Impact factor: 5.157

3.  DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer.

Authors:  Catherine R Sears; Sean A Cooney; Helen Chin-Sinex; Marc S Mendonca; John J Turchi
Journal:  DNA Repair (Amst)       Date:  2016-03-03

4.  DNA-Platinum Thin Films for Use in Chemoradiation Therapy Studies.

Authors:  Mohammad Rezaee; Elahe Alizadeh; Darel Hunting; Léon Sanche
Journal:  Bioinorg Chem Appl       Date:  2011-10-02       Impact factor: 7.778

5.  A bioinformatics filtering strategy for identifying radiation response biomarker candidates.

Authors:  Jung Hun Oh; Harry P Wong; Xiaowei Wang; Joseph O Deasy
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

Review 6.  Inhibition of homologous recombination repair with Pentoxifylline targets G2 cells generated by radiotherapy and induces major enhancements of the toxicity of cisplatin and melphalan given after irradiation.

Authors:  Lothar Bohm
Journal:  Radiat Oncol       Date:  2006-05-03       Impact factor: 3.481

Review 7.  Targeting the ATR-CHK1 Axis in Cancer Therapy.

Authors:  Stuart Rundle; Alice Bradbury; Yvette Drew; Nicola J Curtin
Journal:  Cancers (Basel)       Date:  2017-04-27       Impact factor: 6.639

8.  Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.

Authors:  N J Birkbak; Y Li; S Pathania; A Greene-Colozzi; M Dreze; C Bowman-Colin; Z Sztupinszki; M Krzystanek; M Diossy; N Tung; P D Ryan; J E Garber; D P Silver; J D Iglehart; Z C Wang; D Szuts; Z Szallasi; A L Richardson
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.